Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regulus Therapeutics Inc. - Common Stock (NQ:RGLS)

1.410 +0.010 (+0.71%)
Streaming Delayed Price Updated: 9:30 AM EDT, Mar 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Regulus Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Traders are paying attention to the gapping stocks in Tuesday's session.
Let's have a look at the gap up and gap down stocks in today's session. 
Via Chartmill
Here are the top movers in Wednesday's session.
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
RGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q2 2024
RGLS stock results show that Regulus Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Ball To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Analyst Expectations for Regulus Therapeutics's Future
Via Benzinga
Expert Ratings for Regulus Therapeutics
Via Benzinga
What's Going On With Regulus Therapeutics Stock Monday?
Regulus Therapeutics announced positive results from its study related to the treatment of autosomal dominant polycystic kidney disease (AKPD). 
Via Benzinga
RGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q1 2024
RGLS stock results show that Regulus Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
The $5 Phenoms: 3 Cheap Stocks That Could Skyrocket by 2028
Finding good investing possibilities in the constantly changing stock market might be likened to unearthing buried jewels. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
RGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q4 2023
RGLS stock results show that Regulus Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Gold Down Over 1%; ClearOne Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the S&P 500 index gaining over 1% on Tuesday. The Dow traded up 0.74% to 39,057.10 while the NASDAQ rose 1.41% to 16,245.83. The S&P 500 also... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Nasdaq Surges Over 1%; Blade Air Mobility Shares Plummet
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 1% on Tuesday. The Dow traded up 0.48% to 38,955.84 while the NASDAQ rose 1.12% to 16,198.58. The S&P 500 also... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance. 
Via Benzinga
Dow Gains 100 Points; US Inflation Rate Rises To 3.2% In February
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 100 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.27% to 38,873.55 while the NASDAQ rose... 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Is Kidney Disease-Focused Regulus Therapeutics Stock Trading Higher On Tuesday?
Regulus Therapeutics reports findings for RGLS8429 in ADPKD study—mechanistic dose response, encouraging biomarkers, and an oversubscribed $100M equity placement at $1.60 per share. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are worth checking out this morning as we get into all of the biggest winners and losers for Tuesday! 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Regulus Therapeutics Releases Early Data From Of Investigational For Rare Type Of Kidney Disease
Regulus Therapeutics Inc (NASDAQ: RGLS) released topline results from the first cohort of patients in its Phase 1b Multiple-Ascending Dose (MAD) trial of RGLS8429 for Autosomal Dominant Polycystic  
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Marpai Shares Are Trading Lower By 26%; Here Are 20 Stocks Moving Premarket
Gainers CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) jumped 153% to $5.96 in pre-market trading after jumping 243% on Friday. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting the week with a breakdown of the biggest pre-market stock movers traders need to know about on Monday morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Regulus Therapeutics Shares Are Trading Higher Today
Regulus Therapeutics (NASDAQ: RGLS) shares are trading higher on Thursday after the company announced a $15 million private placement of equity. 
Via Benzinga
Why ViewRay Shares Are Trading Lower By 32%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers CXApp Inc. (NASDAQ: CXAI) jumped 105% to $3.28 after climbing over 20% on Wednesday. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.